Guidelines for new tuberculosis drug released

10/25/2013 | Medscape (free registration)

The Centers for Disease Control and Prevention released provisional guidelines for the use of bedaquiline fumarate in children and pregnant women with multidrug-resistant tuberculosis or patients with extrapulmonary multidrug-resistant TB. The agency urged caution in using bedaquiline with CYP3A4-inhibiting drugs. If options are limited, clinicians can consider using the drug for patients with extrapulmonary TB, pediatric and obstetric patients or people with HIV or other comorbid disorders depending on the circumstances, but it is not routinely recommended pending further studies, the agency said.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC